Advertisement

Amarin Corp., an Irish biopharmaceutical with U.S. operations in Mystic, Conn., said today that its drug candidate AMR101 showed significant decreases in triglycerides during a Phase 3 trial.

The company, which focuses on cardiovascular diseases, said the Phase 3 trial, called Anchor, met its primary and secondary endpoints for both 4-gram and 2-gram doses.

SOURCE

Advertisement
Advertisement